Publications
Detailed Information
Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: Integrating with lung specific GPA score
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Dae-Won | - |
dc.contributor.author | Shin, Dong-Yeop | - |
dc.contributor.author | Kim, Jin Wook | - |
dc.contributor.author | Keam, Bhumsuk | - |
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Kim, Hak Jae | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Wu, Hong-Gyun | - |
dc.contributor.author | Paek, Sun Ha | - |
dc.contributor.author | Kim, Young Whan | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.contributor.author | Kim, Dong Gyu | - |
dc.contributor.author | Lee, Se-Hoon | - |
dc.date.accessioned | 2020-04-27T11:23:32Z | - |
dc.date.available | 2020-04-27T11:23:32Z | - |
dc.date.created | 2020-02-19 | - |
dc.date.issued | 2014-12 | - |
dc.identifier.citation | Lung Cancer, Vol.86 No.3, pp.363-368 | - |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.other | 91727 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165398 | - |
dc.description.abstract | Objective: While several prognostic models have been presented in NSCLC patients with brain metastasis, none of these models have included molecular markers as an index. The aim of our study was to evaluate the prognostic value of EGFR mutations and to integrate these EGFR mutations into the prognostic index in NSCLC patients with brain metastasis. Materials and methods: We analyzed retrospectively 292 lung adenocarcinoma patients with brain metastasis. Clinico-pathological features and overall survival (OS) were compared between patients with EGFR mutations and patients with EGFR wild type. EGFR mutation status was integrated with lung specific graded prognostic assessment (GPA) score. Results: Among 292 patients, EGFR mutation status was tested in 183 patients. One hundred and five patients (57.4%) had EGFR activating mutations, 14 (7.7%) had EGFR non-activating mutations and 64 (35.0%) had EGFR wild type. OS Was significantly longer in patients with EGFR activating mutations than in those with EGFR wild type patients (20.4 vs. 10.1 months, p = 0.002). However, patients with EGFR non-activating mutations did not show superior OS compared with EGFR wild type patients (14.6 vs. 10.1 months, p = 0.83). Multivariate analysis revealed that the presence of EGFR activating mutation is an independent positive prognostic factor for OS (adjusted hazard ratio 0.56, p = 0.002). Conclusions: EGFR activating mutations have a prognostic role in lung adenocarcinoma patients with brain metastasis that is independent of other known prognostic factors. The frequency of EGFR mutation was higher than expected. The presence of EGFR activating mutations should be included as an index in the prognostic models for lung adenocarcinoma patients with brain metastasis. (C) 2014 Elsevier Ireland Ltd. All rights reserved. | - |
dc.language | 영어 | - |
dc.publisher | Elsevier BV | - |
dc.title | Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: Integrating with lung specific GPA score | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.contributor.AlternativeAuthor | 김학재 | - |
dc.contributor.AlternativeAuthor | 우홍균 | - |
dc.contributor.AlternativeAuthor | 백선하 | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.contributor.AlternativeAuthor | 김영환 | - |
dc.contributor.AlternativeAuthor | 김동규 | - |
dc.identifier.doi | 10.1016/j.lungcan.2014.10.001 | - |
dc.citation.journaltitle | Lung Cancer | - |
dc.identifier.wosid | 000347136400012 | - |
dc.identifier.scopusid | 2-s2.0-84964267008 | - |
dc.citation.endpage | 368 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 363 | - |
dc.citation.volume | 86 | - |
dc.identifier.sci | 000347136400012 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kim, Hak Jae | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Wu, Hong-Gyun | - |
dc.contributor.affiliatedAuthor | Paek, Sun Ha | - |
dc.contributor.affiliatedAuthor | Kim, Young Whan | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.contributor.affiliatedAuthor | Kim, Dong Gyu | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | GROWTH-FACTOR-RECEPTOR | - |
dc.subject.keywordPlus | TYROSINE KINASE INHIBITORS | - |
dc.subject.keywordPlus | PHASE-II TRIAL | - |
dc.subject.keywordPlus | RADIATION-THERAPY | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | GEFITINIB | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | ERLOTINIB | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordAuthor | Lung cancer | - |
dc.subject.keywordAuthor | Brain metastasis | - |
dc.subject.keywordAuthor | GPA score | - |
dc.subject.keywordAuthor | EGFR mutation | - |
dc.subject.keywordAuthor | adenocarcinoma | - |
dc.subject.keywordAuthor | prognosis | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.